These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 15169792

  • 1. Signal transducer and activator of transcription-5 activation and breast cancer prognosis.
    Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H.
    J Clin Oncol; 2004 Jun 01; 22(11):2053-60. PubMed ID: 15169792
    [Abstract] [Full Text] [Related]

  • 2. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence.
    Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT.
    Clin Cancer Res; 2005 Aug 15; 11(16):5863-8. PubMed ID: 16115927
    [Abstract] [Full Text] [Related]

  • 3. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.
    Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL.
    Clin Cancer Res; 2003 Feb 15; 9(2):594-600. PubMed ID: 12576423
    [Abstract] [Full Text] [Related]

  • 4. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.
    Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H.
    Endocr Relat Cancer; 2006 Sep 15; 13(3):885-93. PubMed ID: 16954437
    [Abstract] [Full Text] [Related]

  • 5. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM.
    Clin Cancer Res; 2004 Nov 15; 10(22):7621-8. PubMed ID: 15569994
    [Abstract] [Full Text] [Related]

  • 6. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Nov 15; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 7. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L, Bendahl PO, Grabau D, Isola J, Lövgren K, Rydén L, Fernö M.
    Breast Cancer Res Treat; 2008 May 15; 109(2):255-62. PubMed ID: 17636398
    [Abstract] [Full Text] [Related]

  • 8. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 9. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
    Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA.
    Cancer Res; 1992 Mar 01; 52(5):1107-13. PubMed ID: 1737370
    [Abstract] [Full Text] [Related]

  • 10. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U, Eppenberger-Castori S.
    J Clin Oncol; 2006 Sep 10; 24(26):4245-53. PubMed ID: 16963728
    [Abstract] [Full Text] [Related]

  • 11. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T.
    Clin Cancer Res; 2006 Jan 01; 12(1):159-68. PubMed ID: 16397038
    [Abstract] [Full Text] [Related]

  • 12. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE, Russell GB, Zbieranski N, Long R, Johnston S, Williams H, Stackhouse C, Wilkins L, Evans I, Berry P, Rimmer K, Tucker E.
    Cytometry B Clin Cytom; 2004 May 01; 59(1):24-31. PubMed ID: 15108167
    [Abstract] [Full Text] [Related]

  • 13. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
    Anticancer Res; 2004 May 01; 24(4):2391-400. PubMed ID: 15330189
    [Abstract] [Full Text] [Related]

  • 14. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.
    Linder N, Lundin J, Isola J, Lundin M, Raivio KO, Joensuu H.
    Clin Cancer Res; 2005 Jun 15; 11(12):4372-81. PubMed ID: 15958620
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer.
    Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W.
    Clin Cancer Res; 2002 Oct 15; 8(10):3065-74. PubMed ID: 12374673
    [Abstract] [Full Text] [Related]

  • 16. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
    Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3319-28. PubMed ID: 16740753
    [Abstract] [Full Text] [Related]

  • 17. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time.
    Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, Beex LV, Sweep FC.
    J Clin Oncol; 2004 Feb 15; 22(4):691-8. PubMed ID: 14966093
    [Abstract] [Full Text] [Related]

  • 18. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D, Juretić A, Sarcević B, Separović V, Kujundzić-Tiljak M, Hudolin T, Spagnoli GC, Cović D, Samija M.
    Croat Med J; 2006 Feb 15; 47(1):32-41. PubMed ID: 16489695
    [Abstract] [Full Text] [Related]

  • 19. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.
    Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL.
    Breast Cancer Res Treat; 2009 May 15; 115(1):77-85. PubMed ID: 18521745
    [Abstract] [Full Text] [Related]

  • 20. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients.
    Scorilas A, Diamandis EP, Levesque MA, Papanastasiou-Diamandi A, Khosravi MJ, Giai M, Ponzone R, Roagna R, Sismondi P, López-Otin C.
    Clin Cancer Res; 1999 Jul 15; 5(7):1778-85. PubMed ID: 10430082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.